

## *William B. Schwartz Division of Nephrology 2018 Division Publications*

### **2018 Print Publications**

A total of 90 print publications and 12 epublications were authored and/or co-authored by Division members in 2018. An asterisk beside a name indicates a current trainee as an author.

1. Abraham AG, Shafi T, Tighiouart H, Moseley KF, Post WS, **Inker LA**, Coresh J, Shlipak MG, **Levey AS**. Effects of body size and composition on sex differences in measured GFR in a US community-based older cohort (MESA-Kidney). *Am J Kidney Dis* 2018; 72:767-770. Epub 2018 Jul 21; PMID:30041875.
2. Al-Rabadi L, Box T, Singhanian G, Al-Marji C, Agarwal A, Hall I, **Gordon CE**, Tran H. Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates. *Hemodial Int*;2018;22:S45-52; PMID: 29694728.
3. Almeqdadi M, Al-Dulaimi M, Perepletchikov A, Tomera K, **Jaber BL**. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: a case report and literature review. *Clin Nephrol Case Stud*. 2018 Apr 27; 6:4-10. eCollection 2018; PMID:29845002.
4. Adrogué HJ, **Madias NE**. Approach to acid-base disorders. In: Singh AK, Riella LV, editors. *Scientific American nephrology, dialysis, and transplantation*. Decker Intellectual; 2018.
5. Adrogué HJ, **Madias NE**. Respiratory acidosis and alkalosis. In: Singh AK, Riella LV, editors. *Scientific American nephrology, dialysis, and transplantation*. Decker Intellectual; 2018.
6. Aoun J, Nicolas D, Brown JR, **Jaber BL**. Maximum allowable contrast dose and prevention of acute kidney injury following cardiovascular procedures. *Curr Opin Nephrol Hypertens* 2018; 27:121-129; PMID:29261551.
7. Beumer JH, **Inker LA**, **Levey AS**. Improving carboplatin dosing based on estimated GFR. *Am J Kidney Dis* 2018; 71:163-165. Epub 2017 Dec 6; PMID:29217306.
8. Bieber SD, **Weiner DE**. Telehealth and home dialysis: a new option for patients in the United States. *Clin J Am Soc Nephrol* 2018; 13:1288-1290. Epub 2018 Jul 24; PMID:30042227.
9. Björk J, Grubb A, Gudnason V, Indridason OS, **Levey AS**, Palsson R, Nyman U. Comparison of glomerular filtration rate estimating equations derived from creatinine and cystatin C: validation in the Age, Gene/Environment Susceptibility-Reykjavik elderly cohort. *Nephrol Dial Transplant* 2018; 33:1380-1388; PMID:29040701.
10. Bostom A, **Steubl D\***, **Garimella PS**, Franchini N, Roberts MB, Pasch A, Ix JH, Tuttle KR, Ivanova A, Shireman T, Kim SJ, Gohh R, **Weiner DE**, **Levey AS**, Hsu CY, Kusek JW, Eaton CB. Serum uromodulin: a biomarker long-term kidney allograft failure. *Am J Nephrol* 2018; 47:275-282. Epub 2018 Apr 26; PMID:29698955.
11. Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, **Perrone RD**, Torres VE, **Miskulin DC**, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW. ADPKD progression in patients with no apparent family history and no mutation detected by Sanger sequencing. *Am J Kidney Dis* 2018; 71:294-235. Epub 2017 Nov 14; PMID:29203126.
12. Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, **Perrone RD**, Rahbari-Oskoui FF, Steinman TI, Torres VE, The HALT-PKD Investigators. Determinants of progression in early autosomal dominant polycystic kidney disease: is it blood pressure or renin-angiotensin-aldosterone-system blockade? *Curr Hypertens Rev* 2018; 14:39-47; PMID:29564978.
13. Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Brau WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, **Perrone RD**, **Miskulin DC**, Steinman TI, Torres VE; HALT-PKD Trial Investigators. Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post ad-hoc analysis from the HALT-PKD Trials. *Am J Kidney Dis* 2018; 71:666-676. Epub 2018 Jan 3; PMID:29306517.

14. Chang TI, **Sarnak MJ**. Intensive blood pressure targets and kidney disease. *Clin J Am Soc Nephrol* 2018; 13:1575-1577. Epub 2018 May 24; PMID:29798887.
15. Chebib FT, **Perrone RD**, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. *J Am Soc Nephrol* 2018; 29:2458-2470. Epub 2018 Sep 18; PMID:30228150.
16. Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, **Inker LA**, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ. Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study. *Am J Nephrol* 2018; 47:40-47. Epub 2018 Jan 18; PMID:29402767.
17. Cohen-Bucay A, Francis JM, **Gordon CE**. Timing of hepatitis C virus infection treatment in kidney transplant candidates. *Hemodial Int* 2018;22:S61-70;PMID: 29694723.
18. **Dad T**, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, **Miskulin DC**, Rahbari Oskoui F, Flessner MF, **Perrone RD**. Longitudinal assessment of left ventricular mass in autosomal dominant polycystic kidney disease. *Kidney Int Rep* 2018; 3:619-624. eCollection 2018 May; PMID:29854969.
19. **Dad T**, Tighiouart H, Fenton JJ, **Lacson E Jr**, **Meyer KB**, **Miskulin DC**, **Weiner DE**, **Richardson MM**. Evaluation of non-response to the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey. *BMC Health Serv Res* 2018;18:790; PMID:30340585.
20. **Dad T**, Tighiouart H, **Lacson E Jr**, **Meyer KB**, **Weiner DE**, **Richardson MM**. Hemodialysis patient characteristics associated with better experience as measured by the in-center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey. *BMC Nephrol* 2018; 19:340; PMID:30486811.
21. **Drew DA**, Katz R, Kritchevsky S, Ix JH, Shlipak MG, Newman AB, Hoofnagle A, Fried L, **Sarnak MJ**, Gutierrez OM. Fibroblast growth factor 23: a biomarker of kidney function decline. *Am J Nephrol* 2018; 47:242-250. Epub 2018 Apr 5; PMID:29621752.
22. Chronic Kidney Disease Prognosis Consortium. Evans M, Grams ME, Sang Y, *et al* for the Chronic Kidney Disease Prognosis Consortium. *Erratum*: Risk factors for prognosis in patients with severely decreased GFR in *Kidney Int Rep* 2018; 3:625-637. *Kidney Int Rep* 2018 Aug 30; 3(6):1506. eCollection 2018 Nov; PMID:30450480.
23. Falke R, **Levey AS**. Hereditary kidney disease: all family members are affected. *J Am Soc Nephrol* 2018; 29:2451-2452. Epub 2018 Sep 11; PMID:30206142.
24. **Garimella PS**, **Sarnak MJ**. Dyslipidemia. In: Lerman EV, Sparks MA, Topf JM, editors. *Nephrology Secrets 4<sup>th</sup> ed*. Philadelphia: Elsevier; 2018. p. 150-155.
25. **Gilbert SJ**, **Dad T**. Hematuria and proteinuria. In: Gilbert SJ, Weiner DE editors. *National Kidney Foundation Primer on Kidney Diseases*. 7th ed. Philadelphia: Elsevier; 2018. p. 42-50.
26. **Gilbert SJ**. Does the kidney biopsy portend the future of Nephrology? *Clin J Am Soc Nephrol* 2018; 13:681-682. Epub 2018 Apr 18; PMID:29669817.
27. Ginsberg C, Craven TE, Chonchol MB, Cheung AK, **Sarnak MJ**, Ambrosius WT, Killeen AA, Raphael KL, Bhatt UY, Chen J, Chertow GM, Freedman BI, Oparil S, Papademetriou V, Wall BM, Wright CB, Ix JH, Shlipak MG; SPRINT Research Group. PTH, FGF23, and intensive blood pressure lowering in chronic kidney disease participants in SPRINT. *Clin J Am Soc Nephrol* 2018; 13:1816-1824. Epub 2018 Nov 13; PMID:30425104.
28. Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, **Sarnak MJ**, Hoofnagle AN, Rifkin DE, Garimella PS, Ix JH. The 24, 25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: the cardiovascular health study. *Bone* 2018; 107:124-130. Epub 2017 Nov 16; PMID:29155243.
29. González SB, Menga G, Raimondi GA, Tighiouart H, Adrogué HJ, **Madias NE**. Secondary response to chronic respiratory acidosis in humans: a prospective study. *Kidney Int Rep* 2018 Jun 8; 3(5):1163-1170. eCollection 2018 Sep; PMID:30197983.
30. **Gordon CE**, Balk EM, Francis JM. Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guidelines on Hepatitis C in Chronic Kidney Disease. *Seminars in Dialysis* 2018;1-9.

31. **Goyal N, Weiner DE.** The Affordable Care Act, kidney transplant access, and kidney care in the United States. *Clin J Am Soc Nephrol* 2018; 13:982-983. Epub 2018 Jun 21; PMID:29929998.
32. Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, Ho K, Ito S, Marks A, Naimark D, Nash DM, Navaneethan SD, **Sarnak MJ**, Stengel B, Visseren FLJ, Wang AY, Köttgen A, **Levey AS**, Woodward M, Eckardt KU, Hemmelgarn B, Coresh J. Predicting timing of clinic outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. *Kidney Int* 2018; 93:1442-1451. Epub 2018 Mar 29; PMID:29605094.
33. Greeviroj P, Kitrunghaiboon T, Katavetin P, Praditpornsilpa K, Eiam-Ong S, **Jaber BL**, Susantitaphong P. Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: a meta-analysis of randomized controlled trials. *Nephron* 2018; 139:197-210. Epub 2018 Mar 7; PMID:29514156.
34. Gul A, **Miskulin DC**, Harford A, Zager P. In-center hemodialysis: time for a paradigm shift. *J Am Soc Nephrol* 2018; 29:2452-2454. Epub 2018 Sep 5; PMID:30185467.
35. Gupta A, Thomas TS, Klein JA, Montgomery RN, Mahnken JD, Johnson DK, **Drew DA**, **Sarnak MJ**, Burns JM. Discrepancies between perceived and measured cognition in kidney transplant recipients: implications for clinical management. *Nephron* 2018; 138:22-28. Epub 2017 Oct 20; PMID:29049997.
36. Hu JR, Coresh J, **Inker LA**, **Levey AS**, Zheng Z, Rebholz CM, Tin A, Appel LJ, Chen J, **Sarnak MJ**, Grams ME. Serum metabolites are associated with all-cause mortality in chronic kidney disease. *Kidney Int* 2018; 94:381-389. Epub 2018 Jun 2; PMID:29871777.
37. **Inker LA.** A roadmap for estimated glomerular filtration rate: where have we been, where we are now, and where do we need to go? *Adv Chronic Kidney Dis* 2018; 25:4-6; PMID:29499885.
38. **Inker LA**, Korashy FM, **Goyal N**, Lentine KL. Assessment of glomerular filtration rate and end-stage kidney disease risk in living kidney donor candidates: a paradigm for evaluation, selection, and counseling. *Adv Chronic Kidney Dis* 2018; 25:21-30; PMID:29499883.
39. **Inker LA**, Heerspink HL. Evaluation of surrogate end points for progression to ESKD: necessary and challenging. *Am J Kidney Dis* 2018; 72:771-773; PMID:30470295.
40. **Inker LA**, **Levey AS**, Coresh J. Estimated glomerular filtration rate from a panel of filtration markers – hope for increased accuracy beyond measured glomerular filtration rate? *Adv Chronic Kidney Dis* 2018; 25:67-75; PMID:29499889.
41. **Inker LA**, **Levey AS.** Assessment of kidney function in acute and chronic settings. In: Gilbert SJ, Weiner DE, editors. *Primer on Kidney Diseases 7<sup>th</sup> Edition*. Philadelphia: Elsevier; 2018. p. 26-32.
42. **Inker LA**, **Levey AS.** Staging and management of chronic kidney disease. In: Gilbert SJ, Weiner DE, editors. *Primer on Kidney Diseases 7<sup>th</sup> Edition*. Philadelphia: Elsevier; 2018. p. 476-483.
43. **Jaber BL.** Exploring old concepts and new paradigms. *Curr Opin Nephrol Hypertens* 2018; 27(2):93; PMID:29303794.
44. Jadoul M, Berenguer MC, Doss W, Fabrizi F, Izopet J, Jha V, Kamar N, Kasiske BL, Lai CL, Morales JM, Patel PR, Pol S, Silva MO, Balk EM, **Gordon CE**, Earley A, Di M, Martin P. Executive summary of the 2018 KDIGO Hepatitis C in CKD guideline: Welcoming advances in evaluation and management. *Kidney Int* 2018;94(4):663-673; PMID: 30243313.
45. Johnson DS, **Meyer KB.** Delaying and averting dialysis treatment: patient protection or moral hazard? *Am J Kidney Dis* 2018; 72:251-254. Epub 2018 Mar 14; PMID:29548781.
46. Johnson DS, **Meyer KB.** Leading integrated kidney entities of the future. *Adv Chronic Kidney Dis* 2018; 25:523-529; PMID:30527553.
47. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Marriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, **Weiner DE**, Chertow GM. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of the Scientific Workshop organized by the National Kidney Foundation. 71:851-865. Epub 2018 Feb 27; PMID:29496260.
48. Jotwani V, Katz R, Ix JH, Gutierrez OM, Bennett M, Parikh CR, Cummings SR, **Sarnak MJ**, Shlipak MG. Urinary biomarkers of kidney tubular damage and risk of cardiovascular disease and mortality in elders. *Am J Kidney Dis* 2018; 72:205-213. Epub 2018 Mar 27; PMID:29602632.

49. Kraut JA, Lew V, **Madias NE**. Re-evaluation of total CO<sub>2</sub> concentration in apparently healthy younger adults. *Am J Nephrol* 2018; 48:15-20. Epub 2018 Jul 10; PMID:29990967.
50. Kraut JA, **Madias NE**. Re-evaluation of the normal range of serum total CO<sub>2</sub> concentration. *Clin J Am Soc Nephrol* 2018; 13:343-347. Epub 2018 Jan 16; PMID:29339355.
51. Kraut JA, **Madias NE**. Retarding progression of chronic kidney disease: use of modalities that counter acid retention. *Curr Opin Nephrol Hypertens* 2018; 27:94-101; PMID:29140821.
52. Kraut JA, **Madias NE**. Sodium bicarbonate for severe metabolic acidaemia. *Lancet* 2018; 392(10141):3-4. Epub 2018 Jun 14; PMID:29910039. *Erratum* in: *Lancet* 2018 Oct 27; 392(10157):1518.
53. Ku E, Ix JH, Jamerson K, Tangri N, Lin F, Gassman J, Smogorzewski M, **Sarnak MJ**. Acute declines in renal function during intensive BP lowering and long-term risk of death. *J Am Soc Nephrol* 2018; 29:2401-2408. Epub 2018 Jul 13; PMID:30006417.
54. Kupferman J, Ramirez-Rubio O, Amador JJ, López-Pilarte D, Wilker EH, Laws RL, Sennett C, Robles NV, Lau JL, Salinas AJ, Kaufman JS, **Weiner DE**, Scammell MK, McClean MD, Brooks DR, Friedman DJ. Acute kidney injury in sugarcane workers at risk for Mesoamerican nephropathy. *Am J Kidney Dis* 2018; 72:475-482. Epub 2018 Jul 2; PMID:30042041.
55. Ladin K, Pandya R, Kannam A, Loke R, Oskoui T, **Perrone RD, Meyer KB, Weiner DE**, Wong JB. Discussing conservative management with older patients with CKD: an interview study of nephrologists. *Am J Kidney Dis* 2018; 71:627-635. Epub 2018 Feb 1; PMID:29396240.
56. Ladin K, Pandya R, **Perrone RD, Meyer KB**, Kannam A, Loke R, Oskoui T, **Weiner DE**, Wong JB. Characterizing approaches to dialysis decision-making with older adults: a qualitative study of nephrologists. *Clin J Am Soc Nephrol* 2018; 13:1188-1196. Epub 2018 Jul 26; PMID:30049850.
57. Lang J, Katz R, Ix JH, Gutierrez OM, Peralta CA, Parikh CR, Satterfield S, Petrovic S, Devarajan P, Bennett M, Fried LF, Cummings SR, **Sarnak MJ**, Shlipak MG. Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders. *Nephrol Dial Transplant* 2018; 33:986-992; PMID:28992097.
58. Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, **Inker LA**, Coresh J, Chang AR, Grams ME. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. *JAMA Intern Med* 2018; 178:903-910; PMID:29868840.
59. Lentine KL, **Levey AS**, Garg AX; KDIGO Living Kidney Donor Work Group. Core assessment of predonation kidney function: clarification of the 2017 KDIGO Living Donor Guideline. *Am J Kidney Dis* 2018; 72:154-155. Epub 2018 Apr 16; PMID:29673725.
60. **Levey AS**, James MT. Acute kidney injury. *Ann Intern Med* 2018; 168:837; PMID:29868806.
61. **Levey AS**, Tighiouart H, Simon AL, **Inker LA**. In reply to 'How valid are GFR estimation results from the CKD-EPI database?' *Am J Kidney Dis* 2018; 71:447. Epub 2017 Dec 26; PMID:29287800.
62. Li Q, Trivedi AN, Galarraga O, Chernew ME, **Weiner DE**, Mor V. Medicare advantage ratings and voluntary disenrollment among patients with end-stage renal disease. *Health Aff (Millwood)* 2018; 37:70-77; PMID:29309223.
63. Lumlertgul N, Siribumrungwong M, **Jaber BL**, Susantitaphong P. Secondary oxalate nephropathy: a systematic review. *Kidney Int* 2018 Jul 39; 3(6):1363-1372. eCollection 2018 Nov; PMID:30450463. Correspondence - The authors reply. *Kidney Int* 2018 Oct 26; 4:185-186. eCollection 2019 Jan; PMID:30596187.
64. Luo S, Coresh J, Tin A, Rebholz CM, Chen TK, Hayek SS, Tracy M, Lipkowitz MS, Appel LJ, **Levey AS, Inker LA**, Reiser J, Grams ME. Soluble urokinase-type plasminogen activator receptor in Black Americans with CKD. *Clin J Am Soc Nephrol* 2018; 13:1013-1021. Epub 2018 Jun 14; PMID:29903900.
65. **Madias NE**, Adrogué HJ. Respiratory Acidosis and Alkalosis. In: Gilbert SJ, Weiner DE editors. *National Kidney Foundation Primer on Kidney Diseases*. 7th ed. Philadelphia: Elsevier; 2018. p. 152-159.
66. Mindikoglu AL, Opekun AR, Puturi N, Devaraj S, Sheikh-Hamad D, Vierling JM, Goss JA, Rana A, Sood GK, Jalal PK, **Inker LA**, Mohny RP, Tighiouart H, Christenson RH, Dowling TC, Weir MR, Seliger SL, Hurson WR, Howell CD, Raufman JP, Magder LS, Coarfa C. Unique metabolic signature associated with hepatorenal dysfunction and mortality in cirrhosis. *Transl Res* 2018; 195:25-47. Epub 2017 Dec 12; PMID:29291380.

67. **Miskulin DC**, Gassman J, Schrader R, Gul A, Jham M, Ploth DW, Negrea L, Kwong RY, **Levey AS**, Singh AK, Harford A, Paine S, Kendrick C, Rahman M, Zager P. BP in dialysis: results of a pilot study. *J Am Soc Nephrol* 2018; 29:307-316. Epub 2017 Dec 6; PMID:29212839.
68. **Miskulin DC**, **Weiner DE**, Tighiouart H, **Lacson EK Jr**, **Meyer KB**, **Dad T**, Manley HJ. High-dose seasonal influenza vaccine in patients undergoing dialysis. *Clin J Am Soc Nephrol* 2018; 13:1703-1711. Epub 2018 Oct 13; PMID:30352787.
69. Novick TK, Surapaneni A, Shin JI, Ballew SH, Alexander GC, **Inker LA**, Chang AR, Grams ME. Prevalence of opioid, gabapentinoid, and NSAID use in patients with CKD. *Clin J Am Soc Nephrol* 2018; 13:1886-1888. Epub 2018 Nov 8; PMID:30409899.
70. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, **Perrone RD**, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, **Miskulin D**, Chonchol M. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 2018; 29:571-578. Epub 2017 Nov 8; PMID:29118087.
71. Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Hays RD, Chapman AB, **Perrone RD**. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. *Am J Kidney Dis* 2018; 71:225-235. Epub 2017 Nov 14; PMID:29150246.
72. Rao M, **Jaber BL**, **Balakrishnan VS**. Chronic kidney disease and acquired mitochondrial myopathy. *Curr Opin Nephrol Hypertens* 2018; 27:113-120; PMID:29266014.
73. Reddy YNV, Nunes D, Chitalia V, **Gordon CE**, Francis JM. Hepatitis C virus infection in kidney transplantation – changing paradigms with novel agents. *Hemodial Int* 2018;22:S53-S60; PMID: 29694721.
74. **Roehm B**\*, Vest AR, **Weiner DE**. Left ventricular assist devices, kidney disease, and dialysis. *Am J Kidney Dis* 2018; 71:257-266. Epub 2017 Dec 14; PMID:29249390.
75. Sedaghat S, Ding J, Eiriksdottir G, van Buchem MA, Sigurdsson S, Ikram MA, Meirelles O, Gudnason V, **Levey AS**, Launer LJ. The AGES-Reykjavik Study suggests that change in kidney measures is associated with subclinical brain pathology in older community-dwelling persons. *Kidney Int* 2018; 94:608-615. Epub 2018 Jun 28; PMID:29960746.
76. Selamet U, Katz R, Ginsberg C, Rifkin DE, Fried LF, Kritchevsky SB, Hoofnagle AN, Bibbins-Domingo K, **Drew D**, Harris T, Newman A, Gutierrez OM, **Sarnak MJ**, Shlipak MG, Ix JH. Serum calcitriol concentrations and kidney function decline, heart failure, and mortality in elderly community-living adults: the Health, Aging and Body Composition Study. *Am J Kidney Dis* 2018; 72:419-428. Epub 2018 Jun 6; PMID:29885925.
77. Seliger SL, Abebe KZ, Hallows KR, **Miskulin DC**, **Perrone RD**, Watnick T, Bae KT. A randomized clinic trial of metformin to treat autosomal dominant polycystic kidney disease. *Am J Nephrol* 2018; 47:352-360. Epub 2018 May 10; PMID:29779024.
78. Shafi T, **Levey AS**. Measurement and estimation of residual kidney function in patients on dialysis. *Adv Chronic Kidney Dis* 2018; 25:93-104; PMID:29499893.
79. Shin JI, Luo S, Alexander GC, **Inker LA**, Coresh J, Chang AR, Grams ME. Direct oral anticoagulants and risk of acute kidney injury in patients with atrial fibrillation. *J Am Coll Cardiol* 2018; 71:251-252; PMID:29325644.
80. Shin JI, Secora A, Alexander GC, **Inker LA**, Coresh J, Chang AR, Grams ME. Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. *Clin J Am Soc Nephrol* 2018; 13:1144-1152. Epub 2018 Jul 12; PMID:30002224.
81. **Steubl D**\*, **Inker LA**. How best to estimate glomerular filtration rate? Novel filtration markers and their application. *Curr Opin Nephrol Hypertens* 2018; 27:398-405; PMID:30063487.
82. Supiano MA, Lovato L, Ambrosius WT, Bates J, Beddhu S, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, **Weiner DE**, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol M. Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. *PLoS One* 2018 Sep 26; 13(9):e0203305. eCollection 2018; PMID:30256784.
83. Tin A, Nadkarni G, Evans AM, Winkler CA, Bottinger E, Rebholz CM, **Sarnak MJ**, **Inker LA**, **Levey AS**, Lipkowitz MS, Appel LJ, Arking DE, Coresh J, Grams ME. Serum 6-bromotryptophan levels identified as a risk factors for CKD progression. *J Am Soc Nephrol* 2018; 29:1939-1947. Epub 2018 May; PMID:29777021.

84. Tsiptotis E, Price LL, **Jaber BL, Madias NE**. Hospital-associated hypernatremia spectrum and clinical outcomes in an unselected cohort. *Am J Med* 2018; 131:72-82. Epub 2017 Aug 30; PMID:28860033.
85. Waikar SS, Rebholz CM, Zheng Z, Hurwitz S, Hsu CY, Feldman HI, Xie D, Liu KD, Mifflin TE, Eckfeldt JH, Kimmel PL, Vasani RS, Bonventre JV, **Inker LA**, Coresh J; Chronic Kidney Disease Biomarkers Consortium Investigators. Biological variability of estimated GFR and albuminuria in CKD. *Am J Kidney Dis* 2018; 72:538-546. Epub 2018 Jul 18; PMID:30031564.
86. Walther CP, Gutierrez OM, Cushman M, Judd SE, Lang J, McClellan W, Muntner P, **Sarnak MJ**, Shlipak MG, Warnock DG, Katz R, Ix JH. Serum albumin concentration and risk of end-stage renal disease: the REGARDS study. *Nephrol Dial Transplant* 2018; 33:1770-1777; PMID:29281114
87. **Weiner DE, Sarnak MJ**. Cardiac function and cardiac disease in chronic kidney disease. In: Gilbert SJ, Weiner DE editors. *National Kidney Foundation Primer on Kidney Diseases*. 7th ed. Philadelphia: Elsevier; 2018. p. 506-514.
88. **Weiner DE, Sarnak MJ**. Cardiovascular disease in patients with chronic kidney disease. In: Himmelfarb J, Ikizler TA editors *Chronic Kidney Disease, Dialysis, and Transplantation* 4th ed. A companion to Brenner and Rector's *The Kidney*. Philadelphia: Elsevier. 2018. p. 176-193.
89. Weinrauch LA, Claggett B, Liu J, Finn PV, Weir MR, **Weiner DE**, E'Elia JA. Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. *Int J Nephrol Renovasc Dis* 2018 Apr 27; 11:155-164. eCollection 2018; PMID:29760559.
90. Zhang WR, Craven TE, Malhotra R, Cheung AK, Chonchol M, Drawz P, **Sarnak MJ**, Parikh CR, Shlipak MG, Ix JH; SPRINT Research Group. Kidney damage biomarkers and incident chronic kidney disease during blood pressure reduction: a case-control study. *Ann Intern Med* 2018; 169:610-618. Epub 2018 Oct 23; PMID:30357395.

## 2018 Epublications

1. Charytan DM, Himmelfarb J, Ikizler TA, Raj DS, Hsu JY, Landis JR, Anderson AH, Hung AM, Mehrotra R, Sharma S, **Weiner DE**, Williams M, DiCarli M, Skali H, Kimmel PL, Kliger AS, Dember LM; Hemodialysis Novel Therapies Consortium. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (Spin-D): a randomized placebo-controlled, multiple dosage trial. *Kidney Int* 2018; pii:S0085-2538(18)30641-0; doi:10.1016/j.kint.2018.08.034; PMID:30473139.
2. Coresh J, **Inker LA**, Sang Y, Chen J, Shafi T, Post WS, Shlipak MG, Ford L, Goodman K, Perichon R, Greene T, **Levey AS**. Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study. *Nephrol Dial Transplant* 2018 Apr 30; doi:10.1093/ndt/gfy094; PMID:29718360.
3. Idrees N, Almeqdadi M, **Balakrishnan VS, Jaber BL**. Hemodialysis for treatment of levofloxacin-induced neurotoxicity. *Hemodial Int* 2018 Sep 25; doi:10.1111/hdi.12687; PMID:30255655.
4. **Inker LA**, Grams ME, **Levey AS**, Coresh J, Cirillo M, Collins JF, Gansevoort RT, Gutierrez OM, Hamano T, Heine GH, Ishikawa S, Jee SH, Kronenberg F, Landray MJ, Miura K, Nadkarni GN, Peralta CA, Rothenbacher D, Schaeffner E, Sedaghat S, Shlipak MG, Zhang L, van Zuijlen AD, Hallan SI, Kovesdy CP, Woodward M, Levin A; CKD Prognosis Consortium. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium. *Am J Kidney Dis* 2018 Oct 19; pii:S0272-6386(18)30916-8; doi:10.1053/j.ajkd.2018.08.013; PMID:30348535.
5. Kraut JA, **Madias NE**. Intravenous sodium bicarbonate in treating patients with severe metabolic acidemia. *Am J Kidney Dis* 2018 Oct; pii:S0272-6386(18)30914-4; doi:10.1053/j.ajkd.2018.08.011; PMID:30343957.
6. **McCallum W\***, **Sarnak MJ**. Blood pressure target for the dialysis patient. *Semin Dial* 2018 Nov 13; doi:10.1111/sdi.12754; PMID:30422343.
7. McCausland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, **Levey AS**, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Treatment of anemia with darbepoetin prior to dialysis initiation and clinic outcomes: analyses from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *Am J Kidney Dis* 2018 Dec 19; pii:S0272-6386(18)31087-4; doi:10.1053/j.ajkd.2018.10.006; PMID:30578152.
8. Meuwese CL, van Diepen M, Cappola AR, **Sarnak MJ**, Shlipak MG, Bauer DC, Fried LP, Iacoviello M, VAES b,

Degryse J, Khaw KT, Luben RN, Asvold BO, Bjørø T, Vatten LJ, de Craen AJM, Trompet S, Iervasi G, Molinaro S, Ceresini G, Ferrucci L, Dullaart RPF, Bakker SJL, Jukema JW, Kearney PM, Stott DJ, Peeters RP, Franco OH, Vözke H, Walsh JP, Bremner A, Sgarbi JA, Maciel RMB, Imaizumi M, Ohishi W, Dekker FW, Rodondi N, Gussekloo J, den Elzen WPJ; Thyroid Studies Collaboration. Low thyroid function is not associated with an accelerated deterioration in renal function. *Nephrol Dial Transplant* 2018 Apr 18; doi:10.1093/ndt/gfy071; PMID:29654213.

9. Moorthi RN, Doshi S, Fried LF, Moe SM, **Sarnak MJ**, Satterfield S, Schwartz AV, Shlipak M, Lange-Maia BS, Harris TB, Newman AB, Stromeyer ES. Chronic kidney disease and peripheral nerve function in the Health, Aging and Body Composition Study. *Nephrol Dial Transplant* 2018 May 10; doi:10.1093/ndt/gfy102; PMID:29757410.
10. **Weiner DE**, Park M, Tighiouart H, Joseph AA, Carpenter MA, **Goyal N**, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, **Levey AS**, Bostom AG. Albuminuria and allograft failure, cardiovascular events, and all-cause death in stable kidney transplant recipients: a cohort analysis of the FAVORIT Trial. *Am J Kidney Dis* 2018 Jul 20; pii:S0272-6386(18)30763-7; doi:10.1053/j.ajkd.2018.05.015; PMID:30037726.
11. **Wright S**, Doron S, **Sarnak MJ**. Kidney function and hospital-acquired infections: worth a deeper look. *Am J Kidney Dis* 2018 Nov 10; pii:S20272-6386(18)31013-8; doi:10.1053/j.ajkd.2018.08.019; PMID:30424916.
12. Yaqoob M, Wang J, Sweeney AT, Wells C, Rego V, **Jaber BL**. Trends in avoidable hospitalizations for diabetes: experience of a large clinically integrated health care system. *J Healthc Qual* 2018 Jun 4; doi:10.1097/JHQ.145; PMID:29870426.